Skip to content
Clinical Trials – home

Sykehuset Oestfold HF Kalnes

Verified siteinfoFast reply

Norway Kalnesveien 300, 1714 Graalum, Norway

  • 28 trials recruiting
  • Immune thrombocytopenia · Ischaemic stroke · Major depression
  • Adults and children

About Specializations

Sykehuset Oestfold HF Kalnes in Graalum, Norway specialises in clinical trials of conditions such as Immune thrombocytopenia, Ischaemic stroke, Major depression, Atrial fibrillation, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

At Sykehuset Oestfold HF Kalnes, the Department of Cardiology is involved in studies focused on acute myocardial infarction, atrial fibrillation, and prevention of ischemic stroke. This research is centered on testing new treatment approaches and improving protection against serious heart and blood-clotting complications.

  • Preventing recurrent heart attacks in people at risk of acute myocardial infarction
  • Reducing stroke and systemic embolism in atrial fibrillation
  • Lowering the risk of ischemic stroke after recent stroke or high-risk transient ischemic attack

The site’s cardiovascular research aims to strengthen treatment options and improve outcomes for patients with high-risk cardiovascular disease.

Neoplasms

Clinical trials at this hospital also address several forms of cancer, including clear cell renal cancer, melanoma, and Diffuse Large B-Cell Lymphoma. These studies are designed to evaluate newer cancer therapies and compare them with established treatment strategies.

  • Testing combination treatments for advanced clear cell renal cell carcinoma
  • Studying ways to prevent recurrence after resected melanoma
  • Assessing treatment effectiveness in Diffuse Large B-Cell Lymphoma

This research reflects a strong interest in improving survival and long-term disease control across different oncology settings.

Nutritional and Metabolic Diseases

Research in this area includes non-alcoholic steatohepatitis, a liver condition closely linked to metabolic risk factors such as obesity and diabetes. The trial activity is aimed at evaluating safety, tolerability, and biological effects of a potential new therapy for patients with liver fibrosis.

  • Evaluating a new treatment approach for non-cirrhotic NASH with fibrosis
  • Exploring disease mechanisms related to metabolism and liver injury
  • Supporting development of therapies for progressive fatty liver disease

These studies highlight the site’s interest in conditions where metabolic dysfunction contributes to long-term organ damage.

Virus Diseases

The site is participating in research on emerging and widespread viral infections, including mpox virus disease and COVID-19. The trials focus on understanding clinical outcomes and assessing whether antiviral or other treatment strategies can improve recovery in hospitalized patients.

  • Observing outcomes in patients with mpox virus disease
  • Evaluating treatment approaches for hospitalized COVID-19 patients
  • Studying care strategies for coronavirus infection in moderate and severe illness

These infectious disease studies support better care for patients affected by both newly emerging and globally significant viral illnesses.

Hemic and Lymphatic Diseases

Trial activity in this therapeutic area includes Diffuse Large B-Cell Lymphoma, with research aimed at comparing treatment options and improving outcomes for patients with blood cancers. The studies are intended to help define more effective and better-tolerated therapy choices.

  • Comparing treatment strategies for lymphoma
  • Assessing effectiveness in hematologic malignancy
  • Supporting better disease control in blood cancer

This work adds to the site’s broader focus on oncology and treatment optimization.

Pathological Conditions, Signs and Symptoms

Some studies at Sykehuset Oestfold HF Kalnes address acute clinical conditions and symptom-driven care, including patients hospitalized with moderate COVID-19 and those with suspected acute myocardial infarction. The purpose is to test whether new treatments can improve short-term outcomes in urgent care settings.

  • Improving outcomes in hospitalized patients with moderate COVID-19
  • Evaluating treatment response in suspected acute myocardial infarction
  • Supporting faster and more effective management of serious clinical symptoms

These trials reflect a practical focus on conditions where rapid treatment decisions can make a major difference.

Metabolism

In addition to liver disease research, the site contributes to studies connected with metabolism and cardiometabolic risk. This includes work that links metabolic health with cardiovascular and liver outcomes, helping researchers better understand how these conditions interact.

  • Exploring the role of metabolic dysfunction in chronic disease
  • Connecting liver, heart, and vascular health in clinical research
  • Supporting development of treatments for metabolism-related disorders

These investigations broaden the site’s clinical research portfolio beyond single diseases and into shared disease pathways.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Kalnesveien 3001714 GraalumNorway
Recruiting now
28 trials
Conditions studied
52
Partner status
Verified site

More sites in GraalumNorway

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

49 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Study of vicadrostat and empagliflozin combination in patients with type 2 diabetes, high blood pressure and cardiovascular disease

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Safety and Pharmacodynamics of RBD4059 and Apixaban in Patients with Non‑Valvular Atrial Fibrillation: A Randomized Active‑Controlled Study

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Ribocure Pharmaceuticals AB

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A study to evaluate the effectiveness of tenecteplase in patients with acute ischemic stroke who are more than 4.5 hours after their last known well time.

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Major depression+1

Recruiting

A study on ketamine maintenance treatment for patients with treatment-resistant major depression disorder

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Ketamine Hydrochloride
  • Sponsor:Ostfold Hospital Trust

A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia to Evaluate Long-term Safety and Effectiveness

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.

A Study of Mezagitamab Compared to Placebo for Adults with Chronic Primary Immune Thrombocytopenia

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Sponsor:Takeda Development Center Americas Inc.
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.